Multiple attack study on the available triptans in Italy versus placebo

C. Vollono, A. Capuano, D. Mei, D. Ferraro, L. Pierguidi, M. Evangelista, Girolamo Di Trapani

Research output: Contribution to journalArticlepeer-review


The aim of the study is to evaluate the efficacy and tolerability of the five triptans that are commercially available in Italy (zolmitriptan 2.5 mg, rizatriptan 10 mg, sumatriptan 100 mg, almotriptan 12.5 mg and eletriptan 40 mg). The study was conducted in single-blind versus placebo and its duration was 18 months. At the Headache Centre of the 'Agostino Gemelli' Hospital in Rome we selected 42 patients, suffering from headache with and without aura (International Headache Society Committee on Headache Classification, 1988 Cephalalgia 8:1-96), whose headache frequency ranged between 1- and 4-monthly crises. For a total of 25 crises, for every five consecutive crises, a different triptan was taken. The end-points of the study were as follows: response at 2 h, 'pain free' at 2 h and 'sustained pain free' (at 24 h). The intra-patient consistency and the tolerability were also evaluated. Thirty patients completed the study and the statistical analysis was only applied to these patients. No substantial difference in terms of the efficacy of the triptans was noted; all triptans were well tolerated. These results suggest the possibility of testing different triptans in the same patient in order to identify the ideal drug for every patient.

Original languageEnglish
Pages (from-to)557-563
Number of pages7
JournalEuropean Journal of Neurology
Issue number7
Publication statusPublished - Jul 2005


  • Almotriptan
  • Eletriptan
  • Migraine
  • Multiple attack
  • Rizatriptan
  • Sumatriptan
  • Triptans
  • Zolmitriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Multiple attack study on the available triptans in Italy versus placebo'. Together they form a unique fingerprint.

Cite this